Bioactive natural products in COVID-19 therapy

Zhonglei Wang; Zhonglei Wang; Ning Wang; Liyan Yang; Xian-qing Song

doi:10.3389/fphar.2022.926507

Frontiers in Pharmacology (Aug 2022)

Bioactive natural products in COVID-19 therapy

Zhonglei Wang,
Zhonglei Wang,
Ning Wang,
Liyan Yang,
Xian-qing Song

Affiliations

Zhonglei Wang: Key Laboratory of Green Natural Products and Pharmaceutical Intermediates in Colleges and Universities of Shandong Province, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, China
Zhonglei Wang: School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
Ning Wang: General Surgery Department, Ningbo Fourth Hospital, Xiangshan, China
Liyan Yang: School of Physics and Physical Engineering, Qufu Normal University, Qufu, China
Xian-qing Song: General Surgery Department, Ningbo Fourth Hospital, Xiangshan, China

DOI: https://doi.org/10.3389/fphar.2022.926507
Journal volume & issue: Vol. 13

Abstract

Read online

The devastating COVID-19 pandemic has caused more than six million deaths worldwide during the last 2 years. Effective therapeutic agents are greatly needed, yet promising magic bullets still do not exist. Numerous natural products (cordycepin, gallinamide A, plitidepsin, telocinobufagin, and tylophorine) have been widely studied and play a potential function in treating COVID-19. In this paper, we reviewed published studies (from May 2021 to April 2022) relating closely to bioactive natural products (isolated from medicinal plants, animals products, and marine organisms) in COVID-19 therapy in vitro to provide some essential guidance for anti-SARS-CoV-2 drug research and development.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords